Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far
Will Boost From ASCO, Aduhelm Improve Investor Sentiment?
Executive Summary
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
You may also be interested in...
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
SPAC Mergers Take Biopharmas Public, But Valuations Often Sag Post-Closing
Merging with a special purpose acquisition corporation is a viable funding tool, but it may not be the best choice for drug developers far from key milestones.
SPAC Mergers Are Viable Funding Tools, But The Test Is Yet To Come
Dozens of health care-focused special purpose acquisition corporations have gone public during the past two years but many biopharma firms that have merged with SPACs have not performed well to date, raising the question of how long the SPAC boom will last.